Last updated: September 4, 2026
Ivosidenib, formerly AG-120 and marketed as Tibsovo, is an oral, first-in-class inhibitor of mutant isocitrate dehydrogenase-1, or IDH1. The FDA has approved it for IDH1-mutated acute myeloid leukemia, cholangiocarcinoma, and relapsed or refractory myelodysplastic syndromes. Its commercial outlook depends on expansion in newly diagnosed AML, adoption in MDS, continued use in cholangiocarcinoma, and the timing of generic entry.
The drug has a differentiated molecular target and several approved indications, but its addressable population remains biomarker-defined. The principal risks are limited IDH1 prevalence, treatment resistance, competing IDH1 and IDH2 therapies, and potential generic competition after the core patent estate begins to expire.
What is AG-120 and how does ivosidenib work?
AG-120 is ivosidenib, an oral small-molecule inhibitor of mutant IDH1. IDH1 mutations produce the oncometabolite 2-hydroxyglutarate, which disrupts cellular differentiation. Ivosidenib inhibits mutant IDH1 and can promote differentiation of malignant cells rather than directly causing broad cytotoxicity.
The drug is administered once daily as 500 mg tablets in the principal FDA-approved indications. It is marketed by Servier in the United States and is known commercially as Tibsovo.
Core development history
| Milestone |
Date |
Significance |
| Agios begins clinical development of AG-120 |
2010s |
Establishes the IDH1-directed development program |
| FDA approval in relapsed or refractory AML |
July 20, 2018 |
First U.S. approval for ivosidenib |
| FDA approval in previously treated cholangiocarcinoma |
August 25, 2021 |
Expands use into solid tumors |
| FDA approval in newly diagnosed AML for patients unable to receive intensive chemotherapy |
May 25, 2022 |
Moves ivosidenib into frontline treatment |
| FDA approval with azacitidine in newly diagnosed AML |
May 25, 2022 |
Creates a combination-based frontline opportunity |
| FDA approval in relapsed or refractory MDS |
December 2023 |
Adds a fourth U.S. disease setting |
The FDA granted regular or accelerated approval depending on the indication and supporting evidence. The AML indication in patients with newly diagnosed disease who are at least 75 years old or unable to receive intensive induction chemotherapy was supported by the AGILE study of ivosidenib plus azacitidine.[1]
What FDA-approved indications does Tibsovo have?
Ivosidenib is FDA-approved for adult patients with susceptible IDH1 mutations in the following settings:
- Newly diagnosed AML in patients aged 75 years or older or those with comorbidities that preclude intensive induction chemotherapy, as a single agent or in combination with azacitidine.
- Relapsed or refractory AML.
- Previously treated, locally advanced or metastatic cholangiocarcinoma.
- Relapsed or refractory MDS.
The indication requires molecular confirmation of an IDH1 mutation. FDA labeling directs testing with an FDA-approved diagnostic or another validated test.[2]
Approved disease settings
| Disease |
Treatment setting |
Commercial relevance |
| AML |
Relapsed or refractory |
Established use, but limited by small biomarker-defined population |
| AML |
Newly diagnosed, unfit for intensive chemotherapy |
Largest approved growth opportunity |
| AML |
Newly diagnosed with azacitidine |
Supports earlier-line and combination use |
| Cholangiocarcinoma |
Previously treated advanced disease |
Smaller population but high unmet need |
| MDS |
Relapsed or refractory |
Newer indication with potential for commercial expansion |
How large is the ivosidenib market?
The addressable market is concentrated in IDH1-mutated AML. IDH1 mutations occur in approximately 6% to 10% of AML cases, although prevalence varies by age, disease classification, and testing method. IDH1 mutations also occur in a minority of cholangiocarcinoma and MDS cases.[3]
The commercial market is therefore driven by four variables:
- Annual incidence of AML and cholangiocarcinoma.
- IDH1 mutation prevalence.
- Eligibility for treatment based on age, fitness, prior therapy, and disease setting.
- Duration of therapy, particularly in frontline AML and MDS.
The largest opportunity is newly diagnosed AML among older or medically unfit patients. This population has a high unmet need and may remain on therapy for multiple cycles if the patient responds and tolerates treatment. Relapsed or refractory AML generates shorter treatment durations because of disease progression, transplantation, or competing salvage regimens.
Estimated patient opportunity
| Segment |
Estimated annual U.S. patient pool before testing and treatment eligibility |
Commercial assessment |
| Newly diagnosed AML, older or unfit |
Approximately 1,000-2,000 IDH1-mutated patients |
Primary growth segment |
| Relapsed or refractory AML |
Approximately 500-1,000 IDH1-mutated patients |
Established but more volatile |
| Advanced cholangiocarcinoma after prior therapy |
Several hundred IDH1-mutated U.S. patients annually |
Niche, durable-use segment |
| Relapsed or refractory MDS |
Several hundred to more than 1,000 potential patients globally, depending on testing and label interpretation |
Expansion opportunity |
These are market-model estimates rather than Servier guidance. The total global opportunity is larger, particularly in Europe and Japan, but access, pricing, mutation testing, and reimbursement materially affect realized sales.
What is the market projection for Tibsovo?
A reasonable base-case projection is for a mature annual global revenue range of approximately $700 million to $1.0 billion before significant generic erosion. The range assumes continued use in AML, gradual adoption in MDS, stable cholangiocarcinoma demand, and no major loss of exclusivity before the early 2030s.
Scenario-based revenue projection
| Scenario |
2025-2026 |
2029-2030 |
Principal assumptions |
| Downside |
$350 million-$500 million |
$350 million-$550 million |
Slow MDS uptake, competitive pressure, earlier generic challenge |
| Base case |
$500 million-$700 million |
$700 million-$1.0 billion |
Sustained frontline AML adoption and moderate MDS penetration |
| Upside |
$650 million-$850 million |
$1.0 billion-$1.3 billion |
Strong combination use, broader international reimbursement, longer treatment duration |
The base case assumes the newly diagnosed AML indication accounts for roughly half of mature sales. Relapsed or refractory AML would remain important but would contribute a smaller share because of shorter treatment duration and treatment-line attrition. MDS could become the second-largest growth contributor if physicians adopt ivosidenib before intensive chemotherapy, transplantation, or other salvage options.
Reported revenue should be distinguished from market potential. Servier owns the U.S. commercial rights, while Agios receives economic benefits under the parties' transaction and collaboration arrangements. Agios transferred its U.S. oncology business to Servier in 2021 for approximately $1.8 billion in upfront consideration, subject to transaction terms and future payments.[4]
What patents protect ivosidenib?
The principal U.S. patent protection for ivosidenib is based on patents covering mutant IDH1 inhibitors and related chemical matter. The core patent family has an expiration date in the early 2030s, with the principal U.S. term generally reported around March 2033 before any applicable patent-term adjustment or extension.
The Orange Book should be used as the controlling source for current listed patents, pediatric extensions, patent-term adjustments, and any later-added formulation or method-of-use patents.[5]
Core patent profile
| Patent category |
Scope |
Expected commercial effect |
| Composition of matter |
Ivosidenib and related mutant IDH1 inhibitor compounds |
Strongest protection |
| Pharmaceutical composition |
Drug-containing formulations and dosage forms |
Supports product protection |
| Treatment methods |
Use in IDH1-mutated AML and other cancers |
Can delay or complicate generic launch |
| Combination therapy |
Use with azacitidine or other agents |
May protect selected treatment regimens |
| Diagnostic linkage |
Patient selection based on IDH1 mutation |
Supports label-specific prescribing |
The composition-of-matter patent is the key barrier. Formulation and method-of-use patents can provide incremental protection, but they usually do not offer the same scope as a valid compound patent against an ANDA applicant seeking approval for the full product.
When does ivosidenib lose exclusivity?
Ivosidenib is unlikely to face ordinary small-molecule generic competition before the early 2030s if the core composition patent remains enforceable and no successful Paragraph IV challenge accelerates entry.
The commercial exclusivity timeline has several layers:
| Exclusivity type |
Status or timing |
| New molecular entity exclusivity |
Initial U.S. NCE exclusivity expired in 2023 |
| Orphan-drug exclusivity |
Applies to certain approved indications and may expire on an indication-specific schedule |
| Patent protection |
Core protection generally extends into 2033 |
| Pediatric exclusivity |
Must be confirmed through current FDA and Orange Book records |
| Generic entry |
Could occur earlier if an ANDA applicant wins a patent challenge or reaches a settlement |
The first generic entrant could challenge only selected patents while maintaining a Paragraph IV certification against patents it believes are invalid, unenforceable, or not infringed. A generic applicant could also seek approval for a narrower indication if it can avoid patented uses through a section viii statement. That strategy is less straightforward where the product label and main commercial use overlap heavily with patented treatment methods.
Have there been Paragraph IV challenges to Tibsovo?
Publicly disclosed Paragraph IV activity should be tracked through FDA ANDA records, Orange Book updates, and federal court filings. No major generic launch of ivosidenib has established a current U.S. market outcome comparable to products that have already undergone extensive Paragraph IV litigation.
The principal litigation scenarios are:
- A generic applicant challenges the core composition patent.
- A generic applicant accepts the compound patent but disputes formulation or method-of-use patents.
- The parties settle for a license date before the full patent expiration.
- The branded company adds or enforces later-issued method-of-use patents.
- A court determines that one or more Orange Book-listed patents are invalid, unenforceable, or not infringed.
A Paragraph IV notice would be commercially material because the product has high annual treatment cost and a concentrated prescriber base. A successful early entrant could capture substantial volume even if the market remains biomarker-limited.
What is the Orange Book status of Tibsovo?
Tibsovo is an FDA-approved small-molecule prescription drug listed in the Orange Book. Unlike a biologic, it is not subject to the biosimilar pathway. Generic applicants would file abbreviated new drug applications, or ANDAs, and would certify against applicable listed patents.
The relevant Orange Book analysis should examine:
- Active ingredient and dosage form.
- Listed patents and expiration dates.
- Patent-use codes.
- Any pediatric exclusivity.
- Whether patents cover all marketed strengths.
- Whether a later formulation or method patent has been added.
The product's principal regulatory barrier is not biosimilar substitution. It is small-molecule generic substitution supported by patent litigation, regulatory certifications, and possible settlement agreements.
Does ivosidenib face biosimilar risk?
No. Ivosidenib is a chemically synthesized small molecule, not a biologic. Biosimilar competition is therefore not the relevant risk category.
The relevant competitive risks are:
- Generic ivosidenib after patent expiry or successful Paragraph IV litigation.
- Enasidenib, an IDH2 inhibitor, in the broader IDH-mutated AML market.
- Conventional AML combinations such as venetoclax plus azacitidine.
- Intensive chemotherapy and allogeneic transplantation.
- Emerging targeted agents and next-generation IDH inhibitors.
- Molecularly selected clinical-trial therapies.
How does Tibsovo compare with competing IDH-directed drugs?
| Product |
Target |
Company |
Main commercial position |
| Tibsovo, ivosidenib |
Mutant IDH1 |
Servier |
AML, cholangiocarcinoma, MDS |
| Idhifa, enasidenib |
Mutant IDH2 |
Servier |
Relapsed or refractory IDH2-mutated AML |
| Vorasidenib |
Mutant IDH1/IDH2 |
Servier |
Primarily a glioma opportunity, not a direct Tibsovo substitute in current AML use |
| Azacitidine plus venetoclax |
Epigenetic and apoptosis pathway |
Multiple companies |
Broad unfit-AML competitor |
| Intensive AML induction |
Non-targeted chemotherapy |
Multiple providers |
Alternative for fit patients |
Ivosidenib has the broadest approved disease footprint among the IDH-directed products listed above. Its competitive strength is highest when mutation testing is routine, patients cannot tolerate intensive chemotherapy, and physicians value targeted differentiation over broader empiric combinations.
What development work remains for AG-120?
The principal development priorities are commercial expansion and evidence generation rather than discovery of the original molecule. Key areas include:
Frontline AML optimization
Combination use with azacitidine is central to the product's growth strategy. Evidence from the AGILE study showed improved event-free survival and overall survival for ivosidenib plus azacitidine compared with azacitidine alone in newly diagnosed IDH1-mutated AML patients unable to receive intensive chemotherapy.[1]
Further work is likely to focus on:
- Treatment duration and maintenance.
- Use around allogeneic transplantation.
- Minimal residual disease assessment.
- Combination with venetoclax.
- Earlier treatment in newly diagnosed patients.
- Resistance mechanisms and relapse management.
MDS expansion
The relapsed or refractory MDS indication provides access to a population with limited approved targeted options. Market penetration will depend on mutation testing, response durability, transfusion independence, and positioning against hypomethylating agents, transplant, and clinical trials.
Cholangiocarcinoma
The cholangiocarcinoma opportunity is clinically differentiated because IDH1 is a recognized driver mutation in a subset of intrahepatic tumors. Commercial growth is constrained by the small eligible population and competition from chemotherapy, immunotherapy, and other targeted treatments.
What manufacturing and intellectual-property barriers affect ivosidenib?
Ivosidenib does not have the manufacturing complexity of a biologic. It is an oral small molecule with conventional active pharmaceutical ingredient and tablet production requirements. The main manufacturing barriers are:
- Control of active pharmaceutical ingredient quality.
- Reproducible tablet formulation.
- Stability and impurity specifications.
- Bioequivalence to the reference product.
- Commercial-scale supply of the active ingredient.
- Compliance with FDA current good manufacturing practice requirements.
These barriers are meaningful but unlikely to prevent a capable generic manufacturer from entering after patent expiry. Patent scope, regulatory exclusivity, and litigation timing are more important than manufacturing complexity.
What generic launch risks exist for Tibsovo?
The most likely generic-entry sequence is:
- Generic applicant files an ANDA after assessing the listed patents.
- The applicant sends a Paragraph IV notice if it contests patent validity, enforceability, or infringement.
- Servier files patent litigation within the statutory period, potentially triggering a 30-month stay.
- The parties litigate or negotiate a settlement.
- Entry occurs on the patent expiry date, a licensed early-entry date, or an earlier date after a successful court decision.
A first generic could produce a rapid price decline because oral oncology products with concentrated demand are vulnerable to substitution once pharmacy and payer restrictions permit generic dispensing. The size of the decline would depend on the number of entrants, the settlement date, and whether branded Tibsovo retains protected uses.
Key Takeaways
- AG-120 is ivosidenib, marketed as Tibsovo.
- FDA-approved uses cover IDH1-mutated AML, cholangiocarcinoma, and relapsed or refractory MDS.
- Newly diagnosed AML in older or medically unfit patients is the largest commercial growth opportunity.
- Ivosidenib is a small molecule, so generic competition, not biosimilar competition, is the relevant exclusivity risk.
- Core U.S. patent protection is generally expected to extend into the early 2030s, with the principal reported expiration period around 2033.
- A base-case mature global revenue range is approximately $700 million to $1.0 billion before material generic erosion.
- The principal commercial threats are limited biomarker prevalence, competition from azacitidine-venetoclax, resistance, and Paragraph IV litigation.
- Servier controls the commercial platform, while Agios retains transaction-based economic interests from the 2021 oncology-business transfer.
FAQs
Is AG-120 the same drug as Tibsovo?
Yes. AG-120 is the development code for ivosidenib, and Tibsovo is the marketed brand name.
Is ivosidenib approved for first-line AML?
Yes. The FDA approved ivosidenib alone or with azacitidine for newly diagnosed IDH1-mutated AML in patients aged 75 or older or those unable to receive intensive induction chemotherapy.
Can generic manufacturers make ivosidenib before 2033?
They may attempt an earlier launch through a Paragraph IV patent challenge or settlement. Routine generic entry is more likely after expiration of the enforceable core composition patent and any relevant later patents.
Is Tibsovo used in IDH2-mutated cancer?
No. Tibsovo targets mutant IDH1. Enasidenib targets mutant IDH2.
What is the biggest upside driver for the ivosidenib market?
The largest upside driver is deeper adoption of ivosidenib plus azacitidine in newly diagnosed, medically unfit AML, followed by broader use in relapsed or refractory MDS and additional combination development.
References
- U.S. Food and Drug Administration. (2022). FDA approves ivosidenib with azacitidine for newly diagnosed acute myeloid leukemia. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Tibsovo prescribing information. Servier Pharmaceuticals LLC.
- DiNardo, C. D., et al. (2018). Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. New England Journal of Medicine, 378(25), 2386-2398.
- Agios Pharmaceuticals, Inc. (2021). Agios announces completion of transaction with Servier for U.S. rights to oncology products.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm